Das Klinikum

Dr. med. Chiara De-Colle

Dr. med. Chiara De-Colle

Oberärztin

Oberärztin für Strahlentherapie mit Schwerpunkte Brustkrebs, Lungenkrebs, Lymphome, personalisierte Strahlentherapie, MR-geführte Strahlentherapie

Kontakt

Telefonnummer: 07071 29-85900

E-Mail-Adresse: chiara.de-colle@med.uni-tuebingen.de

Klinik / Institut / Zentrum

  • 09/2004–10/2010Studienabschluss Medizin und Chirurgie, Universität Turin (Italien). Abschlussarbeit: The use of Four Dimensional Computed Tomography (4D-CT) in the treatment planning of stereobody radiation therapy for lung tumors: clinical results and future perspective.
  • 09/2014–12/2015Forschungsaufenthalt an der Universitätsklinik für Radioonkologie Tübingen. Thema: Strahlenbiologie, DNA repair, prognostic biomarkers für eine personalisierte Strahlentherapie
  • 06/2011–07/2016Facharztausbildung Strahlentherapie, Universität Turin (Italien)
  • 09/2016-12/2016Gastwissenschaftlerin Radioonkologie, Universtität Tübingen. Thema: prognostic biomarkers für eine personalisierte Strahlentherapie mit Focus HNO-Tumoren und Prostatakarzinom
  • 09/2018Promotion, Eberhard-Karls-Universität Tübingen. Doktorarbeit: SDF-1/CXCR4 as prognostic markers for postoperative radiochemotherapy in head and neck cancer
  • 01/2017-09/2022Fachärztin in der Klinik für Radioonkologie, Eberhard-Karls-Universität Tübingen
  • seit 10/2022Oberärztin in der Klinik für Radioonkologie, Eberhard-Karls-Universität Tübingen
  • “Adaptive radiotherapy for breast cancer”. C. De-Colle et al. Clinical and Translational Radiation Oncology 39 (2023) 100564
  • “Radiotherapy and hyperthermia for breast cancer patients at high risk of recurrence”. C. De-Colle et al. Int J Hyperthermia, Aug 2022
  • “Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC – Hypothesis generation on a multicentre cohort of the DKTK-ROG”, Löck S, Linge A, Lohaus F, Ebert N, Gudziol V, Nowak A, Tinhofer I, Kalinauskaite G, Guberina M, Stuschke M, Balermpas P, von der Grün J, Grosu AL, Debus J, Ganswindt U, Belka C, Peeken JC, Combs SE, De-Colle C, Zips D, Baretton GB, Krause M, Baumann M for the DKTK-ROG. Radiotherapy and Oncology Apr 2022
  • “Estimation of secondary cancer projected risk after partial breast irradiation at the 1.5 T MR-linac”. C. De-Colle et al. Strahlenther Onkol. 2022, May 10.
  • “Analysis of the electron-stream effect in patients treated with partial breast irradiation using the 1.5 T MR-linear accelerator”. C. De-Colle et al. Clinical and Translational Radiation Oncology 27 2021, 103–108.
  • “γH2AX foci assay in glioblastoma: Surgical specimen versus corresponding stem cell culture”. A. Riedel, L. Klumpp, A. Menegakis, C. De-Colle, S. M. Huber, J. Schittenhelm et al. Radiotherapy and Oncology 159 2021, 119–125
  • “Optimizing MR-Guided Radiotherapy for Breast Cancer Patients”. M. L. Groot Koerkamp, J. E. Vasmel, N. S. Russell, S. F. Shaitelman, C. N. Anandadas, A. Currey, D. Vesprini, B. M. Keller, C. De-Colle, K. Han et al. Front. Oncol. 2020, 10:1107
  • “Partial breast irradiation with the 1.5 T MR-Linac: First patient treatment and analysis of electron return and stream effects”. M. Nachbar, D. Mönnich, S. Boeke, C. Gani, N. Weidner, V. Heinrich, M. lo Russo, L. Livi, J. Winter, S. Tsitsekidis, O. Dohm, D. Thorwarth, D. Zips, C. De-Colle. Radiotherapy and Oncology 145 2020, 30–35
  • “Hyperthermic chest wall re-irradiation in recurrent breast cancer: a prospective observational study”. C. De-Colle, N. Weidner, V. Heinrich, S. et al. Strahlenther Onkol. 2019 Jan 3.
  • "SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy". C. De-Colle, A. Menegakis, D. Mönnich et al. Radiotherapy and Oncology (2017)
  • "Ex vivo γH2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity". C. De-Colle, A. Yaromina, J. Hennenlotter et al. Radiotherapy and Oncology (2017) 3, 386-394
  • "SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy". C. De-Colle, D. Mönnich, S. Welz et al. Clinical and Translational Radiation Oncology (2017) 5, 28-36
  • "Residual γH2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness". A. Menegakis, C. De-Colle, A. Yaromina et al. Radiotherapy and Oncology 116 (2015) 480-485
  • "Hypofractionation with no boost after breast conservation in early stage breast cancer patients". F. Arcadipane, P. Franco, C. De-Colle et al. Medical Oncology (2016) 33:108
  • "Once-weekly hypofractionated whole breast radiotherapy after breast conserving surgery in older patients: a potential alternative treatment schedule to daily 3-week hypofractionation". P. Rovea, A. Fozza, P. Franco, C. De-Colle et al. Clinical Breast Cancer, Vol. 15 (2015), No. 4, 270-6
  • Publikationen
  • European Society for Radiotherapy and Oncology (ESTRO)
  • Deutsche Gesellschaft für Radioonkologie (DEGRO)